AngioDynamics, Inc. (NASDAQ: ANGO) has announced the appointment of Eric Honroth as the company’s President and Chief Executive Officer, effective November 2, 2026. He will succeed James C. Clemmer, who is retiring from the role. Mr. Clemmer has served as CEO since April 2016 and will step down on the Effective Date.
Mr. Honroth, age 55, joins AngioDynamics from Getinge AB, where he served as President of Life Science from 2018 to 2026. Prior to that, he held senior leadership roles at Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific. He is a graduate of Miami University and has been appointed to the company’s Board of Directors concurrently with his appointment as CEO.
In connection with the appointment, the company and Mr. Honroth entered into an employment agreement on October 3, 2026. The agreement stipulates a base salary of $735,000 per year. Mr. Honroth is eligible for an annual bonus at a target level of 95% of his base salary.
Upon the Effective Date, Mr. Honroth will receive a long-term incentive award with a grant-date value of $1,487,116, consisting of 50% restricted stock units and 50% performance share units. Additionally, he will receive a one-time restricted stock unit award valued at $450,000 to replace compensation forfeited from his prior employer, and a cash sign-on bonus of $350,000.
Mr. Honroth will also receive a monthly commuting and temporary living allowance of $10,000 for up to 24 months, an automobile allowance of $24,000 annually, and reimbursement for reasonable travel and lodging expenses. The agreement details severance terms, including continued base salary payments and accelerated vesting of equity awards under specific termination scenarios, including a Change in Control.
Separately, the company has entered into a consulting agreement with Mr. Clemmer, effective October 5, 2026, for him to provide services until the first anniversary of the Effective Date. He will receive a consulting fee of $30,000 per month. The Board has also approved retention agreements for the company’s executive leadership team, which accelerate the vesting of equity grants upon termination under certain conditions.
